


Liposome for Drug Delivery

Liposomes are lipid-based nanoparticles used extensively in the pharmaceutical and cosmetic industries because of their capacity for breaking down inside cells, once their delivery function has been met.

Liposomes were the first engineered nanoparticles used for drug delivery but problems such as their propensity to fuse together in aqueous environments and release their payload, have lead to replacement, or stabilization using newer alternative nanoparticles.



<http://en.wikipedia.org/wiki/File:Liposome.jpg>
<http://biotech.about.com/od/nanotechnology/a/typesnanopart.htm>

MKK 8/04/11

Hyperthermia Enables Tumor-specific Nanoparticle Delivery: Effect of Particle Size

1Garheng Kong, Rod D. Braun, and Mark W. Dewhirst2

Department of Biomedical Engineering [G. K.] and Department of Radiation Oncology [R. D. B., M. W. D.], Duke University Medical Center, Durham, North Carolina 27710

ABSTRACT

The efficacy of novel cancer therapeutics has been hampered by the ability to deliver these agents to the tumor at effective concentrations. Liposomes have been used as a method to overcome some delivery issues and, in combination with hyperthermia, have been shown to increase drug delivery to tumors. Particle size has been shown to affect the delivery of liposomes, but it is not known how hyperthermia affects size dependence. This study investigates the effect of hyperthermia (42°C) on the extravasation of different sized nanoparticles (albumin; 100-, 200-, and 400-nm liposomes) from tumor microvasculature in a human tumor (SKOV-3 ovarian carcinoma) xenograft grown in mouse window chambers. In this model (at 34°C), no liposomes were able to extravasate into the tumor interstitium. Hyperthermia enabled liposome extravasation of all sizes. The magnitude of hyperthermia-induced extravasation was inversely proportional to particle size. Thus, at normothermia (34°C), the pore cutoff size for this model was between 7 and 100 nm (e.g., liposomes did not extravasate). At 42°C, the pore cutoff size was increased to >400 nm, allowing all nanoparticles tested to be delivered to the tumor interstitium to some degree. With hyperthermia, the 100-nm liposome experienced the largest relative increase in extravasation from tumor vasculature. Hyperthermia did not enable extravasation of 100-nm liposomes from normal vasculature, potentially allowing for tumor-specific delivery. These experiments indicate that hyperthermia can enable and augment liposomal drug delivery to tumors and potentially help target liposomes specifically to tumors.

[CANCER RESEARCH 60, 4440–4445, August 15, 2000]


MKK 8/04/11

Buckyballs and Carbon Nanotubes

Both members of the fullerene structural class, carbon based, lattice-like, potentially porous molecules.


Buckyballs are spherical in shape

Carbon tubes are cylindrical. The diameter of a carbon tube can be several nm but the length can be much greater, up to several mm, depending on its intended use.



Buckminsterfullerene C60, also known as the buckyball, is the smallest member of the fullerene family.

Bone cells grown on carbon nanotubes



Laura Zanello, University of California, Riverside

<http://en.wikipedia.org/wiki/Nanomaterials>

<http://biotech.about.com/od/nanotechnology/a/typesnanopart.htm>

Nanoshells

Also referred to as core-shells, nanoshells are spherical cores of a particular compound surrounded by a shell or outer coating of another, which is a few nanometers thick.

Once the nanoshells enter tumor cells and radiation treatment is applied, they absorb the energy and heat up enough to kill the cancer cells.

Table 1. Average tumor heating in nanoshell-treated and nanoshell-free controls

Mouse	$\Delta T \pm SD$	
	Control	Nanoshell
1	4.7 \pm 0.7	39.7 \pm 4.7
2	8.4 \pm 1.6	60.4 \pm 3.4
3	9.1 \pm 2.5	44.6 \pm 6.0
4	5.9 \pm 1.2	32.8 \pm 1.2
5	8.7 \pm 0.9	28.1 \pm 1.0
6	7.6 \pm 1.6	32.5 \pm 0.7

<http://biotech.about.com>



Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance

L. R. Hirsch*, R. J. Stafford†, J. A. Banksont†, S. R. Sershen*, B. Rivera†, R. E. Price†, J. D. Hazlet†, N. J. Halas§, and J. L. West**

PNAS November 11, 2003 vol. 100 no. 23 13549–13554

(AP) Tiny gold nanoshells that contain a bit of mica in their center. A group of Texas researchers injected the nanoshells - so small it would take 5,000 of them to reach the size of a poppy seed - into tumors in mice. They then exposed the tumors to near infrared radiation, heating them enough to kill the cancer but without injuring nearby normal tissue.

Quantum Dots

The photoluminescence from different sized quantum dots

Quantum Dots: Also known as nanocrystals, quantum dots are nanosized semiconductors that, depending on their size, can emit light in all colours of the rainbow.

These nanostructures confine conduction band electrons, valence band holes, or excitons in all three spacial directions.

Examples of quantum dots are semiconductor nanocrystals and core-shell nanocrystals, where there is an interface between different semiconductor materials.

They have been applied in biotechnology for cell labelling and imaging, particularly in cancer imaging studies.

MKK 8/04/11 <http://biotech.about.com/od/nanotechnology/a/typesnanopart.htm>

Quantum dots light up individual DNA binding proteins

DNA-binding proteins

Transcription factors
Various polymerases
Nucleases
Histones

Experimental steps for mapping DNA binding proteins.

a) Crosslinking DNA-binding proteins (black) to DNA

b) Staining DNA (blue), quantum dot labeling of bound proteins (green), and labeling of specific reference sequences on DNA with quantum dots (red).

c) Complexes are aligned on a glass coverslip and imaged by a fluorescence microscope. Image analysis provides information on protein location.

d) Pseudo color image of RNAP-biotin crosslinked to aligned DNA and bound to streptavidin quantum dots of 4 different colors (Scale-bar 10 μ m). (Image: Dr. Ebenstein, UCLA)

<http://www.kusoz.com/blog/>
Nano Letters, "Lighting Up Individual DNA Binding Proteins with Quantum Dots"

MKK 8/04/11

Magnetic nanoparticles

Class of nanoparticle which can be manipulated using magnetic fields

Commonly consist of magnetic elements such as iron, nickel, cobalt & their chemical compounds

Biologically functionalized magnetic nanoparticle

Chemically functionalized magnetic nanoparticle

Magnetic core

Functional coating

Biological ligand (e.g. antibody)

Receptor-mediated interaction

Nonspecific interaction

Receptor-bound nanoparticle

Living cell

Hyperthermia

Another interesting therapy is based on the ability of MNPs to be heated when a time-varying magnetic field is applied.

TEM of 15nm Fe₃O₄ magnetic nanoparticles

images.pennnet.com

A Magnetically Triggered Composite Membrane for On-Demand Drug Delivery

Todd Hoare¹, Jesus Santamaria², Gerardo F. Goya³, Silvia Irusta², Debora Lin¹, Samantha Lau¹, Robert Padera¹, Robert Langer¹, and Daniel S. Kohane¹

McMaster University, Hamilton, Ontario; University of Zaragoza, Zaragoza, Spain; Harvard Medical School, MA

Nano Lett., 2009, 9 (10), pp 3651–3657

Minimal or No Flux

Strong Flux

Membrane

Nanogel

Magnetic ON





Drug Reservoir


Drug Concentration

Time (minutes)

Nanocomposite membranes based on thermosensitive, poly(N-isopropylacrylamide)-based nanogels and magnetite nanoparticles have been designed to achieve "on-demand" drug delivery upon the application of an oscillating magnetic field. On-off release of sodium fluorescein over multiple magnetic cycles has been successfully demonstrated using prototype membrane-based devices. The total drug dose delivered was directly proportional to the duration of the "on" pulse. The membranes were nontoxic, were biocompatible, and retained their switchable flux properties after 45 days of subcutaneous implantation.

MKK 8/04/11







An Ideal Smart Therapeutic Nanodevice


Targets to Tumor
or Stromal Elements (Angiogenic Endothelial Cells)
Specifically or Non-specifically
Has Imaging Capability to Document Presence in Tumor
Delivers Therapeutic Agents Based on Tumor Characteristics
Might Use Non-invasive External Trigger to Release Therapeutics
Documents Response to Therapy
Identifies Residual Tumor cells

M. Khan,

MKK 8/04/11



Synthesis of Dendrimer Nanocomposites



Dendrimers provide uniform polymeric template molecules in variable sizes and with tunable compatibility. The resulting "soft" composite nanoparticles combine the properties of the encapsulated inorganic matter and the biofriendly macromolecule


Balogh, Swanson, Spindler, Tomalia, *Proc. ACS PMSE*, 1997, 77, 118
 Balogh and Tomalia: "Nanocomposites of Dendritic Polymers" **US 6,664,315 B2**, (2003), **US 6,475,994** (2002),
 Balogh, et al., "Dendrimer-based Nanoscopic Sponges and Metal Composites" **US 5,938,934** (1999).

MKK 8/04/11

Possible Multifunctional Architectures Based on Dendrimers

Dendrimer

Composite Nanodevice



Functional termini are covalently attached to the dendrimer - a tough synthetic task


The composite nanodevice carries the therapeutic and/or other functions in its interior - a simple approach

MKK 8/04/11

Biodistribution Studies

First task is to know the biodistribution of the host as $f(\text{size, charge})$


B16F10 melanoma cells (or MatLyLu) were grown on the dorsal surface of a mouse C57Bl6/J (or athymic nude) mice. The mouse was then injected via tail vein with the nanocomposite solution (400 μg of DNC each).



<http://www.brainresci.com/metabolic.htm>

L.Balogh.....M.K. Khan, Nanomedicine 2007


MKK 8/04/11



MKK 8/04/11

Size, Charge and Other Factors Effect Interaction of Nanoparticles with Complex Biologic Systems

DOD- DAMD17-03-1-0018
M. Khan and L. Balogh



MKK 8/04/11





Fig. B3. Basic components of pharmacodynamic models.³⁵

MKK 8/04/11



MKK 8/04/11



MKK 8/04/11

Toxicity Assessment


MKK 8/04/11

In Vitro Toxicity Analysis Tumor Cell and Normal Cells

In Vivo Toxicity Analysis (Long and Short-term)
Clinical toxicity tables
Weight measures
Serum Analysis
Histochemical tissue analysis
Inflammation markers
Immune reactions

MKK 8/04/11

5 nm {Au} Composite Nanodevices Shows No Clinical Toxicity



MKK 8/04/11

Submitted to Nanomedicine

In Vivo – Serum Analysis {Au} Composite Nanodevices

Routine CBC (Complete Blood Cell Count)

WBC White Blood Cells
 RBC Red Blood Cells
 HGB Hemoglobin
 HCT Hematocrit
 PLT Platelet Count


Electrolytes

Na
 K
 Ca
 Phos
 Glucose
 BUN
 Creatinine
 Total Protein
 Albumin
 Cholesterol

Routine Differential

White Blood Cells
 Neutrophils
 Monocytes
 Eosinophils
 Basophils


MKK 8/04/11



Inflammation

MKK 8/04/11


Inflammation: Rocket Immuno-Electrophoresis



MKK 8/04/11

Nanoletters, Submitted

Possible Multifunctional Nanodevice Architectures



MKK 8/04/11




MKK 8/04/11




Can we Modify the Surface of the Nanoparticles to Permit Direct Targeting?

MKK 8/04/11






MKK 8/04/11



MKK 8/04/11

Folate-Targeted Nanoparticle Delivery of Chemotherapy

Decreased Tumor Growth
Increased Survival
Decreased Toxicity




MKK 8/04/11

Cancer Res. 2005 Jun 15;65(12):5317-24

IMAGING

MKK 8/04/11

Nanocomposite Molecular Imaging Currently Under Investigation




MKK 8/04/11

Imaging Nanocomposites Targeting Tumor Microvasculature



RO1 - Mohamed Khan, M.D., Ph.D.
L. Balogh, Ph.D., Co-PI

The objective is to improve early detection and understanding of cancer by developing an imaging approach based on radioactive nanocomposite devices (NCDs) allowing multi-modality imaging

Target: $\alpha_v\beta_3$ integrin







^{198}Au and ^{67}Cu containing nanocomposites




Methods:
TEM - Intracellular/Cellular Imaging
Autoradiography - Multicellular/Tissue
SPECT - Whole Animal Imaging

Nanocomposites may be directed to the tumor microvasculature by: differing size and charge, or by using surface moieties that specifically target the angiogenic tumor microvasculature


MKK 8/04/11



Hyperspectral Imaging of Mouse Prostate Tumor



Targeted CND in Tumor




MKK 8/04/11

Images post 48-hr-In Vivo, Real-time, Live Mice

Control
(Streptavidin-AlexaFluor-680: 5 µg)

LBMK-21 (Au-5cRGD-BT6-CND: 2.5 µg
& SA-AlexaFluor680: 5 µg)



MKK 8/04/11

Kavanas et al. in preparation




MKK 8/04/11

Radiation THERAPY and Isotopes

MKK 8/04/11

Potential Forms of Radiotherapy:



Gamma rays



Electrons

Beta particles
(e⁻s generated in nuclear decay)

Protons




Neutrons

Alpha Particles





MKK 8/04/11


Prostate Brachytherapy


MKK 8/04/11



NanoBrachytherapy and NanoSTART (Systemic Targeted NanoRadiation Therapy): Targeting the Angiogenic Microvasculature for cancer TREATMENT




Tail vein injections



Target = $\alpha_v\beta_3$ integrin


DOD-
M. Khan and L. Balogh

MKK 8/04/11



Possible Multifunctional Nanodevice Architectures

Nanocomposite



Drug-Delivery indicator


Contrast Agent (x-ray, MRI)

Sensor-Cell death

Therapeutic module

Cancer cell targeting

MKK 8/04/11



Nanocomposites-Imaging and Therapy

Mohamed Khan, MD, PhD
and
Lajos Balogh, PhD

**Muhammad Taju Kariapper, PhD*
**Venu Kastagopalan, PhD*
Bindu Nair, PhD
**Wojciech Lesniak, PhD*
**M. Tayib Ould Ely, PhD*
**David Rigual, M.S.*
Shraddha Nigevakar, PhD
Lok Yun Sung
Alla Kwitny
Kerstin S. May
Areej El-Jawhri
Mikel Llanes
Brian Bolton, MD
Fatema Mamou, MPH
Marion Seggio
Emily Waite
Hanna Roy
Remy Bezimungu
Cindy Ta, MD

Nuclear Reactor
**Leah Minc, PhD*
Christopher Becker, PhD

Physics-Imaging/Therapy
**Peter Roberson, PhD*
**Andras Sablauer, MD, PhD*
Manju Sharma, PhD
**Daniel Nazereth, PhD*
**Matthew Podgorsak, Ph.D.*

Nuclear Medicine-Imaging
**Michael Haka, MD*

Folate Collaborators
James R. Baker, MD
Kimberly Candido, MD
Istvan Majoros, PhD
Balazs Keszler, PhD

PK/PD:
**Don Mager, PhD*
**Gerald Federley*
**Allen Forrest, PhD*
**Patrick Smith, PhD*

Engineering:
**Matthew O'Donnell, Ph.D.*

TEM:
Dorothy Sorenson, BA
Christopher Edwards, BA



Toxicity Analysis:
**Peter Kanter, DVM, PhD*
**K. Toth, MD*




Immunology-Inflammation:
**Heinz Bauman, Ph.D.*

Statistics:
**Alan Hutson, PhD*
Matthew Schipper, PhD

MKK 8/04/11







MKK 8/04/11



MKK 8/04/11